Sam – Page 204 – biolegacy

Johnson & Johnson Employee Pleads With CEO, Lawmakers to Help Save DACA

Post author:Sam
Post published:January 11, 2018
Post category:BioPharma

A federal judge has temporarily blocked the Trump administration's efforts to wind down DACA. Source: BioSpace

FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer

Post author:Sam
Post published:January 11, 2018
Post category:BioPharma

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace

Athenex Moves Forward With $205M New York Plant

Post author:Sam
Post published:January 11, 2018
Post category:BioPharma

According to a SEC filing, the cost of the facility will be paid in part by the State of New York. Source: BioSpace

CellMark Hit With Consent Decree Over Cancer Treatment Ads

Post author:Sam
Post published:January 11, 2018
Post category:Drug Industry Daily

The Federal Trade Commission took CellMark Biopharma to federal court for falsely advertising two of its supplements as “clinically proven” to treat cancer and cancer treatment side effects. Source: Drug…

Study: FDA Should Increase Social Media Use to Issue Safety Information

Post author:Sam
Post published:January 11, 2018
Post category:Drug Industry Daily

A new CDER-funded study says the FDA is not taking full advantage of social media to communicate drug safety information — and should, for example, be making more use of…

FDA Policy Roadmap Targets Opioid Addiction, Strengthening Generic Competition

Post author:Sam
Post published:January 11, 2018
Post category:Drug Industry Daily

The FDA will prioritize the opioid crisis, innovation, and generic competition in the coming year, the agency said in a 2018 Strategic Policy Roadmap released Thursday. Source: Drug Industry Daily

Suitors Weigh Bids for Sanofi's $3B European Generics Biz

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

The portfolio consists of acute, chronic and oncology products. Source: BioSpace

PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe. Source: BioSpace

What You Need to Know About Hyalex Orthopaedics

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage. Source: BioSpace

4 Major Biopharmas: What Went Down at JPM 2018

Post author:Sam
Post published:January 10, 2018
Post category:BioPharma

Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference. Source: BioSpace